Deutsches Krebsforschungszentrum

Ruprecht-Karls-Universitat Heidelberg

Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts

Hexal Pharma Gmbh

Ruprecht-Karis-Universität Heidelberg

Hexal Gentech Forschungsgmbh

Hexal Gentech Forschungs Gmbh

Ruprecht-Karls-Universität

Michael Dahm

Jean Rommelaere

Barbara Leuchs

Karsten Geletneky

Wolfgang Wick

Ottheinz Krebs

Antonio Marchini

Christiane Dinsart

Assia Angelova

Dirk Jager

Marcus Müller

Veronika Frehtman

Dirk Jäger

Antje Wick

Robert Phelps

Robert C Phelps

Carsten Brockmeyer

Marcus Muller

The present invention provides a robust single clone Master Cell Bank (MCB) for an optimized production of H-1 parvovirus (H-1 PV) which is suitable to increase infectious parvovirus production compared to standard producer NB-324K mixed cells.

Optimized parvovirus H-1 production

The present invention concerns a pharmaceutical composition where a checkpoint inhibitor is combined with an oncolytic virus and the use of said combination for the treatment of cancer.

Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor

Described is a parvovirus formulation which comprises (a) at least 1&#xd7;10pfu/ml of parvovirus H1 (H-1PV) or a related rodent parvovirus such as LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus or Rat virus (RV) and (b) a pharmaceutically acceptable carrier containing 40-50% Iodixanol (w/v), 0.7-0.9 mmol CaCl&#xd7;2 HO, 50-60 mmol NaCl, 0.9-1.2 mmol KCl, 0.7-0.95 mg/ml Tromethamine and 0.05-0.15 mg/ml Edetate calcium disodium. A preferred use is the therapy of a brain tumour by intratumoral injection.

Parvovirus formulation for treating tumors

Described is a pharmaceutical composition comprising (a) a parvovirus and (b) bevacizumab and the use of said composition for treatment of cancer, e.g., a solid tumor.

Cancer therapy with a parvovirus combined with bevacizumab

The invention relates to a method of preparing an original sample () of biological origin with a view to detecting at least one component contained in it, whereby the original sample () is enclosed in a first container () and at least a part of this original sample () is transferred from the first container () into at least one reaction container, a reagent () or reagent mixture being placed beforehand in at least one of the reaction containers in order to prepare the original sample () and the component to be detected. In order to transfer at least a part of the original sample (), two respective containers () are connected to one another to form a closed, airtight system at least until at least the component(s) to be detected has (have) been rendered stable by reacting it (them) with the reagent () or reagent mixture at room temperature.

Method and device for preparing a sample of biological origin in order to determine at least one constituent contained therein

The invention relates to a method for enriching tumor cells from a body fluid, in which a cell separation medium of a specific density is overlaid with the body fluid and it is subsequently determined whether the enriched cells express an epithelial marker, for example a cytokeratin. A kit suitable for this method is likewise provided.

Method for the immunocytological or molecular detection of disseminated tumor cells from a body fluid and kit that is suitable therefor

The invention relates to a method for the enrichment or depletion of tumor cells from a body fluid, in which a cell separation medium of specific density is overlaid with the body fluid and is centrifuged. A kit suitable for this method is likewise provided.

Method for the enriching or depleting tumor cells obtained from a body fluid and kit suitable for this purpose

Growing community of inventors

Munich, Germany

Michael Dahm